0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > 2019-nCoV proteins > Spike RBD > RAS-T029

Anti-SARS-CoV-2 (B.1.351) Antibody IgG Titer Serologic Assay Kit (Spike RBD)

For research use only.
Materials Provided
IDComponentsSize
RAS029-C01Pre-coated SARS-CoV-2 Spike RBD(B.1.351) Microplate1 plate
RAS029-C02Positive Control100 μL
RAS029-C03Negative Control100 μL
RAS029-C04HRP-Anti-Human IgG200 μL
RAS029-C0510xWashing Buffer50 mL
RAS029-C06Dilution Buffer50 mL
RAS029-C07Substrate Solution12 mL
RAS029-C08Stop Solution7 mL
  • Background
    Multiple variants of SARS-CoV-2 are circulating globally and posting new challenges to human health. The variant B.1.351 identified in South Africa shows evidence of increased transmissibility and resistance to established immunity. There are 10 mutations on the spike protein of the South African variant (L18F, D80A, D215G, LAL242-244del, R246I, K417N, E484K, N501Y, D614G, A701V); of which 3 (K417N, E484K, N501Y) resides on the receptor-binding domain (RBD). To evaluate the impacts of the new variants, a rapid and effective assay kit detecting the levels of antibody against the mutant is in urgent need.
  • Application
    This kit is developed for serologic test for IgG titer of Anti-SARS-CoV-2 Spike RBD antibody in serum/plasma in vitro. The Spike RBD antigen used in this kit contains K417N, E484K, N501Y mutations found in the South African variant (known as B.1.351 or 20C/501Y.V2).
    It is for research use only.
  • Storage

    The unopened kit is stable for at least 1 year from the date of manufacture if stored at 2°C to 8°C, and the opened kit is stable for up to 1 month from the date of opening at 2°C to 8°C.

  • Assay Principles
    This assay kit employs a standard indirect-ELISA format, providing a rapid detection of Anti-SARS-CoV-2 antibodies in serum by SARS-CoV-2 Spike RBD. The kit consists of Pre-coated SARS-CoV-2 Spike RBD Microplate, an Positive Control, an Negative Control, an HRP-Anti-Human IgG secondary antibody and related buffer.

    Your experiment will include 4 simple steps:

    a) Add your sample to the plate. The samples and Control sample are diluted by Dilution Buffer.

    b) Add diluted Secondary antibody HRP-Anti-Human IgG to the plate. The Secondary antibody is diluted by Dilution Buffer.

    c) Wash the plate and add TMB or other colorimetric HRP substrate.

    d) Stop the substrate reaction by add diluted acid. Absorbance (OD) is calculated as the absorbance at 450 nm minus the absorbance at 650 nm to remove background prior to statistical analysis. The OD Value reflects the amount of antibody bound.

Typical Data
Anti-SARS-CoV-2 (B.1.351) Antibody IgG Titer Serologic Assay Kit (Spike RBD)Anti-SARS-CoV-2 (B.1.351) Antibody IgG Titer Serologic Assay Kit (Spike RBD) (Cat. No. RAS-T029) ELISA bioactivity

Detection of Monoclonal Anti-SARS-CoV-2 Antibody IgG titer by Indirect-ELISA Assay.
Immobilized SARS-CoV-2 Spike RBD at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-SARS-CoV-2 Antibody, Human IgG in 1:400 human serum. Detection was performed using HRP-Anti-human IgG antibody with sensitivity of 156 ng/mL (QC tested).

Comments (0)

Order Details

Price(USD) : $650.00

Promotion & Exhibitions



Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop